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ADDITIONAL FILE 1
MSCs expansion and release criteria:
Due to limited availability but in parallel urgent requirement of MSCs for treatment of our 
patients, we obtained MSCs from two different institutions (University of Tuebingen and 
University of Frankfurt am Main, respectively). Standardized expansion protocols, each with 
slight modifications, and release criteria were as follows:
MSCs expansion and release criteria for Case A:  20ml heparinized bone marrow were 
harvested by iliac crest puncture from a healthy 45-year-old female donor (previously tested 
for viral infections) using a protocol approved by the University
 of Tuebingen Institutional 
Review Board. All cell culture steps were performed in a GMP facility. Red blood cells were 
removed by ammonium chloride lysis for 10 min at room temperature. Lysis buffer consisted 
of 8.29g ammonium chloride, 1g potassium hydrogencarbonate, 0.037g Na2EDTA/H2O, 
added to 1000ml ddH2O and filter sterilized. The remaining cells were washed once in PBS. 
Cells were resuspended in 50ml of low glucose DMEM (Cambrex, Verviers, Belgium) 
supplemented with 1mM Glutamine (Cambrex), 5% (v/v) human fresh frozen plasma (FFP), 
5% platelet lysate (from single donor platelet concentrate at 10
8/ml, University of Tuebingen 
blood donor center) and 80IU/ml heparin sulphate. Cells were incubated at 37°C under 10% 
CO2  in a T175 tissue culture flask with vented cap. After 48h non-adherent cells were 
removed. At 80% confluency cells were detached with recombinant trypsin, washed and re-
plated in two T175 tissue culture flasks, then 10 and after 2 weeks finally in 40 flasks (three 
passages in total). MSCs were harvested, washed, resuspended in 50ml physiological NaCl 
solution containing 0.1% human albumin (Octapharma, Langefeld, Germany), passed through 
a 70 mm cell strainer (Corning Inc., Corning, NY) and transfused over a period of 15 min. 
Release criteria included culture for less than 6 weeks, viability >75%, absence of T-cells, 
lack of CD45 and expression of CD73, CD90 and CD105 by more than 90% of the cells as 
assessed by flow cytometry. Sterility tests were performed at the start of the culture and 
during the last passage 1 week before administration. 
MSCs expansion and release criteria for Case B:  30ml of bone marrow aspirate were 
obtained from the posterior iliac crest of a healthy 17-year-old male donor (previously tested 
for viral infections) under whole anesthesia using a protocol approved by the University
 of 
Frankfurt am Main Institutional Review Board. All cell culture steps were performed in a GMP facility. The bone marrow aspirate was diluted 1:2 in PBS and after that two volumes of 
the samples were layered over 1 volume ficoll (density: 1.077 g/ml) (Biochrom, Berlin, 
Germany) in a 50ml conical tube and centrifuged at 700 x g for 30 min without brake. 
Mononuclear cells were then collected from the interface, washed twice with PBS and 
centrifuged at 400 x g for 10 min. The cell pellet was resuspended in low-glucose DMEM 
with GlutaMAX™ I  (Gibco/Invitrogen, Darmstadt, Germany) supplemented with 10% of 
MSCs-qualified FBS (Invitrogen) and plated in T175 tissue culture flasks with vented caps at 
a concentration of 1.7x10
5 cells/cm
2. The cells were cultured in an incubator with 5% CO2 and 
95% humidity at 37°C. After 72h non-adherent cells were removed, whereas the adherent cell 
fraction was further cultured in fresh culture medium. Culture medium was changed every 4 
days and once the MSCs reached a 70-80% confluence, they were detached with recombinant 
trypsin (TrypLE™ Select, Invitrogen), washed and further re-plated in new T175 tissue 
culture flasks. After 3 passages (P3) the MSCs were frozen in DMEM supplemented with 
30% FBS and 10% DMSO. Before transplantation the MSCs were thawed and washed 3 
times with CliniMACs buffer (Miltenyi Biotec, Bergisch-Gladbach, Germany) supplemented 
with 0.5% human serum albumin (HSA) (Baxter, Heidelberg, Germany). After the last wash 
step  the MSC pellets  were collected  and  resuspended  in  100  ml  CliniMACS buffer 
supplemented with 0.5% human albumin and administered to the patient. Release criteria 
included sterility tests performed at the start of the culture and at the end of passage 3 before 
MSCs were cryoconserved, viability >75%, absence of T-cells, lack of CD45 and expression 
of CD73, CD90 and CD105 by more than 90% of the cells as assessed by flow cytometry.